{Reference Type}: Journal Article
{Title}: Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients.
{Author}: Yingling SK;Francis J;Seago K;Safi SUD;Wen S;Cumpston A;
{Journal}: Support Care Cancer
{Volume}: 32
{Issue}: 5
{Year}: 2024 Apr 9
{Factor}: 3.359
{DOI}: 10.1007/s00520-024-08480-9
{Abstract}: <B>OBJECTIVE: </B>To study the effects of delaying pegfilgrastim administration following high-dose cytarabine (HiDAC) consolidation in AML patients on time to neutrophil count recovery, infectious complications, and survival.<BR><B>METHODS: </B>Single-center retrospective chart review of 55 patients receiving pegfilgrastim as early administration (within 72 h) or delayed administration (after 72 h) of HiDAC.<BR><B>RESULTS: </B>The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, p < 0.28). Infections were seen in four patients in the early administration group following chemotherapy compared to none in the delayed group (p = 0.04). Febrile neutropenia rates were also decreased in the delayed administration group (23.1% versus 10.3%, p = 0.28) as well as a trend towards longer median survival (16 months versus 19 months, p = 0.69) and overall survival (21 months versus 31 months, p = 0.47).<BR><B>CONCLUSIONS: </B>A difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed administration of pegfilgrastim in these patients.